Mark Watling

1.7k citations

29 papers · 982 indexed · h-index 16

Impact in

Biological Psychiatry top 5%
- Tryptophan and brain disorders
Neurology top 5%
- Neuroinflammation and Neurodegeneration Mechanisms

Papers in ⓘ

Biological Psychiatry 3
- Tryptophan and brain disorders 3
Physiology 16
- Alzheimer's disease research and treatments 15

Co-authors: Bruno P. Imbimbo (16 shared papers)Madia Lozupone (6 shared papers)Francesco Panza (6 shared papers)Stefania Ippati (6 shared papers)Vincenzo Solfrizzi (3 shared papers)Claudia Balducci (4 shared papers)A. Knight (3 shared papers)Alexander Fisher (2 shared papers)
Journals: Alzheimer s & Dementia (3 papers)Expert Opinion on Investigational Drugs (3 papers)Annals of the Rheumatic Diseases (2 papers)Expert Opinion on Drug Discovery (2 papers)Blood Coagulation & Fibrinolysis (1 paper)
Partner nations: Italy United Kingdom Belgium

In The Last Decade

Mark Watling

28 papers receiving 964 citations

Peers

Countries citing papers authored by Mark Watling

Since Specialization

Citations

This map shows the geographic impact of Mark Watling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Watling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Watling more than expected).

Fields of papers citing papers by Mark Watling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Watling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Watling. The network helps show where Mark Watling may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Watling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Watling Line = papers co-authored together Mark Watling links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation Annals of the Rheumatic Diseases ·Sophie Glatt, Dominique Baeten, Terry Baker, Meryn Griffiths, Lucian Ionescu, Alastair D. G. Lawson, Ash Maroof, Ruth Oliver, Serghei Popa, Foteini Strimenopoulou, Pavan Vajjah, Mark Watling, Nataliya Yeremenko, Pierre Miossec, Stevan Shaw	2017	204
2	Time to test antibacterial therapy in Alzheimer’s disease Brain ·Francesco Panza, Madia Lozupone, Vincenzo Solfrizzi, Mark Watling, Bruno P. Imbimbo	2019	129
3	Investigational BACE inhibitors for the treatment of Alzheimer’s disease Expert Opinion on Investigational Drugs ·Bruno P. Imbimbo, Mark Watling	2019	96
4	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders Nature Reviews Neurology ·Francesco Panza, Madia Lozupone, Davide Seripa, Antonio Daniele, Mark Watling, Gianluigi Giannelli, Bruno P. Imbimbo	2020	71
5	Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study Annals of the Rheumatic Diseases ·Sophie Glatt, Peter C. Taylor, Iain B. McInnes, Georg Schett, Robert Landewé, Dominique Baeten, Lucian Ionescu, Foteini Strimenopoulou, Mark Watling, Stevan Shaw	2019	49
6	Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188 International Journal of Clinical Pharmacology and Therapeutics ·Alexander Fisher, Mark Watling, Arlene Smith, A. Knight	2010	48
7	Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies Pharmacological Research ·Bruno P. Imbimbo, Stefania Ippati, Mark Watling, Camillo Imbimbo	2022	45
8	Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 – 800 µg in healthy volunteers International Journal of Clinical Pharmacology and Therapeutics ·Alexander Fisher, Mark Watling, Alexandra A. Smith, A. Knight	2010	45
9	A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies Alzheimer s & Dementia ·Bruno P. Imbimbo, Stefania Ippati, Mark Watling, Claudia Balducci	2021	45
10	Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story Neural Regeneration Research ·Bruno P. Imbimbo, Claudia Balducci, Stefania Ippati, Mark Watling	2022	33
11	Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study* British Journal of Dermatology ·Ruth Oliver, James G. Krueger, Sophie Glatt, Pavan Vajjah, Catrina Mistry, Matthew Page, Hannah B Edwards, Sandra Garcet, Xuan Li, Benjamin Dizier, A. Maroof, Mark Watling, Assem el Baghdady, Dominique Baeten, Lucian Ionescu, Stevan Shaw	2021	32
12	Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives Expert Opinion on Investigational Drugs ·Bruno P. Imbimbo, Madia Lozupone, Mark Watling, Francesco Panza	2020	25
13	What have we learned from past failures of investigational drugs for Alzheimer’s disease? Expert Opinion on Investigational Drugs ·Bruno P. Imbimbo, Mark Watling	2021	20
14	Plasma ATN(I) classification and precision pharmacology in Alzheimer's disease Alzheimer s & Dementia ·Bruno P. Imbimbo, Mark Watling, Camillo Imbimbo, Robert Nisticò	2023	18
15	Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease? Therapeutic Advances in Chronic Disease ·Filomena Lo Vecchio, Paola Bisceglia, Bruno P. Imbimbo, Madia Lozupone, Raffaela Rita Latino, Emanuela Resta, Maurizio Leone, Vincenzo Solfrizzi, Antonio Greco, Antonio Daniele, Mark Watling, Francesco Panza, Davide Seripa	2022	17
16	Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease? Alzheimer s & Dementia ·Madia Lozupone, Bruno P. Imbimbo, Claudia Balducci, Filomena Lo Vecchio, Paola Bisceglia, Raffaela Rita Latino, Maurizio Leone, Vittorio Dibello, Vincenzo Solfrizzi, Antonio Greco, Antonio Daniele, Mark Watling, Davide Seripa, Francesco Panza	2022	17
17	Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer’s disease or should they be looking elsewhere? Expert Opinion on Drug Discovery ·Bruno P. Imbimbo, Stefania Ippati, Mark Watling	2020	15
18	Accelerating Alzheimer’s disease drug discovery and development: what’s the way forward? Expert Opinion on Drug Discovery ·Bruno P. Imbimbo, Stefania Ippati, Mark Watling, Claudia Balducci	2021	14
19	First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases European Journal of Clinical Pharmacology ·Eric Helmer, Mark Watling, Emma Jones, D. Tytgat, Mark Jones, Rodger A. Allen, Andrew Payne, Annelize Koch, Eugene Healy	2017	13
20	Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease? Alzheimer s & Dementia Translational Research & Clinical Interventions ·Bruno P. Imbimbo, Stefania Ippati, Ferdinando Ceravolo, Mark Watling	2020	13

About Mark Watling

Mark Watling is a scholar working on Biological Psychiatry, Physiology, Anesthesiology and Pain Medicine, Psychiatry and Mental health and Pharmacology, having authored 29 papers that have together received 982 indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (15 papers), Cholinesterase and Neurodegenerative Diseases (6 papers), Dementia and Cognitive Impairment Research (5 papers), Pain Management and Opioid Use (3 papers), Parkinson's Disease Mechanisms and Treatments (3 papers), Tryptophan and brain disorders (3 papers), Psoriasis: Treatment and Pathogenesis (3 papers) and Cancer Treatment and Pharmacology (2 papers). The work is most often cited by research in Biological Psychiatry (73 citations), Neurology (138 citations), Physiology (426 citations), Immunology (249 citations) and Anesthesiology and Pain Medicine (61 citations). Mark Watling has collaborated with scholars based in Italy, United Kingdom and Belgium. Frequent co-authors include Bruno P. Imbimbo, Madia Lozupone, Francesco Panza, Stefania Ippati, Vincenzo Solfrizzi, Claudia Balducci, A. Knight, Alexander Fisher, Dominique Baeten and Lucian Ionescu. Their work appears in journals such as Alzheimer s & Dementia, Expert Opinion on Investigational Drugs, Annals of the Rheumatic Diseases, Expert Opinion on Drug Discovery and Blood Coagulation & Fibrinolysis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact